Schools, colleges and states that require students to be immunized against COVID-19 may be at risk of losing federal money ...

Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...

The Pentagon says the military services must again ask troops who were forced out or who voluntarily left the military due to ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

Novartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug ...

Vaccines are designed to guard babies, toddlers, and older children against a whole range of serious and potentially deadly ...

Food and drug companies have expressed optimism, but the new health secretary and his MAHA movement will likely make waves.

All this negativity, however, does open up an opportunity for investors to buy the stock at a discount. Despite being a top ...

As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives ...

Pfizer faces revenue decline from patent expirations, profitability challenges, and bearish technicals. Learn why PFE stock ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Laura is an editor and staff writer at IFLScience. She obtained her Master's in Experimental Neuroscience from Imperial College London.